Good call if you listen to it. Mentioned that sales this Qtr are...

Good call if you listen to it. Mentioned that sales this Qtr are back to expected levels and that large number of VAC approvals expected this Qtr/Next. One of the 4million dollar costs was a one off with Permeaderm onboarding.

With ReCell Go approval end of the month it makes sense to wait for international roll out strategy with the new and best technology. ReCell Go inventory was confirmed as ready to go day 1.

As a anaesthetist, working closely with surgeons, my opinion is the uptake acceleration with ReCell Go is likely to be very significant, but of course JC is being conservative with projections which is smart as he has maybe overstepped the enthusiasm before and we get a run up of SP followed by a drop with any negative news. I can tell you that surgeons, like all humans, will always be attracted to "convenience". Less training, less OT time, excellent clinical results with less patient grafting = strong encouragement to adopt. The argument that the spray on skin cell suspensions are now standardised in Recell Go, rather than relying on physician manual disaggregation is also a much more scientific feel to it which as doctors, we like.

All still on track to becoming the global standard of care for a majority of SSG's across the developed world within a few years - and then Vitiligo on top, as well as wound synergies with dressings, wound scaffolds. Current Market Cap just a drop in the ocean of where this will be within a few short years. If this all works out as planned and this grows to become a ASX 100 company within a few years where will the SP be then? First major step is ReCell GO launch. Second major step is profitability in 2025.

Again, don't consider selling until profitability IMO. Certainly I will not nor any of my medical colleague that are holders and are firm believers we discuss this often and look forward to the Australian roll out.